FDL176
/ Flatley Discovery Lab
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 27, 2018
Safety, tolerability and pharmacokinetics of the CFTR potentiator FDL176
(ECFS Belgrade 2018)
- "In combination with CFTR corrector FDL169, it has similar in vitro efficacy to lumacaftor/ivacaftor under acute conditions and higher under chronic conditions. FDL176 is well tolerated and demonstrated a favorable safety profile in healthy subjects. Safety and PK profile support further development of FDL176."
Clinical • PK/PD data • Biosimilar • Dermatology • Immunology
February 05, 2020
A DDI Study of FDL169 and FDL176 in Healthy Subjects
(clinicaltrials.gov)
- P1/2; N=78; Suspended; Sponsor: Flatley Discovery Lab LLC; Recruiting ➔ Suspended
Clinical • Trial suspension
August 01, 2019
A DDI Study of FDL169 and FDL176 in Healthy Subjects
(clinicaltrials.gov)
- P1/2; N=78; Recruiting; Sponsor: Flatley Discovery Lab LLC; Phase classification: P1 ➔ P1/2; N=32 ➔ 78; Trial completion date: Mar 2019 ➔ Feb 2020; Trial primary completion date: Mar 2019 ➔ Feb 2020
Clinical • Enrollment change • Phase classification • Trial completion date • Trial primary completion date
1 to 3
Of
3
Go to page
1